# US 6,727,226 B2 · Mu-conopeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,226 B2
- Document ID: US6727226B2
- Status: Granted
- Kind: B2
- Application number: 09/910,009
- Filed: 2001-07-23
- Published: 2003-03-13
- Granted: 2004-04-27
- Earliest claimed: 2000-07-21
- Assignees: University of Utah Research Foundation; Cognetix, Inc.
- Inventors: Baldomero M. Olivera; J. Michael McIntosh; James E. Garrett; Lourdes J. Cruz; Robert M. Jones; G. Edward Cartier; John D. Wagstaff
- Web page: https://patentgrep.com/patent/US6727226B2

## CPC

- C07K 14/43504: {from invertebrates}
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 23/00: Anaesthetics
- A61P 23/02: Local anaesthetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is to μ-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the μ-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The μ-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the μ-conopeptides and encoding propeptides, as well as the propeptides.

## Claims

### Claim 1

An isolated peptide comprising the amino acid sequence Xaa—Asn—Cys—Cys—Asn—Gly—Gly—Cys—Ser—Ser—Lys—Xaa—Cys—Arg—Asp—His—Ala—Arg—Cys—Cys (SEQ ID NO:211), wherein Xaa at position 1 is Gln or pyro-Glu and Xaa at position 12 is Trp or bromo-Trp.

### Claim 2 (depends on 1)

The isolated peptide of claim 1, wherein Xaa at position 1 is pyro-Glu and Xaa at position 12 is Trp.

### Claim 3

An isolated μ-conopeptide propeptide comprising the amino acid sequence Gly-Ser-Met-Met-Ser-Lys-Leu-Gly-Val-Leu-Leu-Thr-Val-Cys-Leu-Leu- Leu-Phe-Pro-Leu-Thr-Ala-Leu-Pro-Leu-Asp-Gly-Asp-Gln-Pro-Ala-Asp-Arg-Pro-Ala-Glu-Arg-Met- Gln-Asp-ASp-Ile-Ser-Ser-Asp-Glu-His-Pro-Leu-Phe-Asp-Lys-Arg-Gln-Asn-Cys-Cys-Asn-Gly-Gly- Cys-Ser-Ser-Lys-Trp-Cys-Arg-Asp-His-Ala-Arg-Cys-Cys-Gly-Arg (SEQ ID NO:210).

### Claim 4 (depends on 1)

A method for treating or preventing disorders associated with voltage gated neuronal sodium channel disorders in which comprises administering to a patient in need thereof a therapeutically effective amount of a peptide of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein said disorder is a neurologic disorder.

### Claim 6 (depends on 5)

The method of claim 5, wherein said neurologic disorder is Amytrophic Lateral Sclerosis.

### Claim 7 (depends on 5)

The method of claim 5, wherein said neurologic disorder is head trauma.

### Claim 8 (depends on 5)

The method of claim 5, wherein said neurologic disorder is epilepsy.

### Claim 9 (depends on 5)

The method of claim 5, wherein said neurologic disorder is a neurotoxic injury associated with conditions of hypoxia, anoxia or ischemia.

### Claim 10 (depends on 9)

The method of claim 9, wherein said neurotoxic injury is associated with stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drownings, suffocation, perinatal asphyxia, or hypoglycemic events.

### Claim 11 (depends on 4)

The method of claim 4, wherein said disorder is pain.

### Claim 12 (depends on 11)

The method of claim 11, wherein said pain is migraine, acute pain, persistent pain, chronic pain, neuropathic pain or nociceptive pain.

### Claim 13 (depends on 12)

The method of claim 12, wherein the pain is phantom limb pain, neuroma pain or pain associated with trigeminal neuralgia, diabetic neuropathy, and post-herpetic neuralgia.

### Claim 14 (depends on 11)

The method of claim 11, wherein said pain is burn pain.

### Claim 15 (depends on 4)

The method of claim 4, wherein said disorder is myofacial pain syndrome, chronic muscle spasm, or spasticity.

### Claim 16 (depends on 1)

A method of alleviating pain which comprises administering to a mammal that is either exhibiting pain or is about to be subjected to a pain-causing event a pain-alleviating amount of a peptide of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the peptide is administered as a local anesthetic.

### Claim 18 (depends on 16)

The method of claim 16, wherein the peptide is administered as an occular anesthetic.
